Literature DB >> 7517569

The effect of neutralizing monoclonal antibodies on early events in Rift Valley fever virus infectivity.

T G Besselaar1, N K Blackburn.   

Abstract

Monoclonal antibodies (mAb) were used to examine possible stages at which antibody-mediated neutralization of Rift Valley fever virus occurs, and to assess whether binding of antibody is dependent on viral protein structure in order that antibody recognition take place. Analysis of the structural properties of the antigenic determinants revealed that the neutralizing sites are highly conformation-dependent. None of the mAb prevented virus binding, suggesting that the epitopes they define are spatially separate from the site(s) responsible for virus attachment to the cellular receptor. The finding that many of the mAb also did not inhibit virus entry into the cell demonstrated that neutralization of RVFV infectivity by immune antibodies is not dependent on blocking at the early stages in the viral life cycle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517569     DOI: 10.1016/s0923-2516(07)80002-1

Source DB:  PubMed          Journal:  Res Virol        ISSN: 0923-2516


  12 in total

1.  Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep.

Authors:  Bonto Faburay; William Wilson; D Scott McVey; Barbara S Drolet; Hana Weingartl; Daniel Madden; Alan Young; Wenjun Ma; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2013-08-20       Impact factor: 2.133

2.  In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus.

Authors:  Jian Ma; Ruifeng Chen; Weijin Huang; Jianhui Nie; Qiang Liu; Youchun Wang; Xiaoming Yang
Journal:  Hum Vaccin Immunother       Date:  2019-06-20       Impact factor: 3.452

3.  Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization.

Authors:  Raquel Martín-Folgar; Gema Lorenzo; Hani Boshra; Javier Iglesias; Francisco Mateos; Belén Borrego; Alejandro Brun
Journal:  MAbs       Date:  2010-05-02       Impact factor: 5.857

4.  A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep.

Authors:  Bonto Faburay; Maxim Lebedev; D Scott McVey; William Wilson; Igor Morozov; Alan Young; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2014-10       Impact factor: 2.133

Review 5.  Current Status of Rift Valley Fever Vaccine Development.

Authors:  Bonto Faburay; Angelle Desiree LaBeaud; D Scott McVey; William C Wilson; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2017-09-19

6.  Characterization of Two Neutralizing Antibodies against Rift Valley Fever Virus Gn Protein.

Authors:  Meng Hao; Guanying Zhang; Shengnan Zhang; Zhengshan Chen; Xiangyang Chi; Yunzhu Dong; Pengfei Fan; Yujiao Liu; Yi Chen; Xiaohong Song; Shuling Liu; Changming Yu; Jianmin Li; Xianzhu Xia
Journal:  Viruses       Date:  2020-02-27       Impact factor: 5.048

7.  An assembly model of rift valley Fever virus.

Authors:  Mirabela Rusu; Richard Bonneau; Michael R Holbrook; Stanley J Watowich; Stefan Birmanns; Willy Wriggers; Alexander N Freiberg
Journal:  Front Microbiol       Date:  2012-07-19       Impact factor: 5.640

8.  Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.

Authors:  Nina Lagerqvist; Jonas Näslund; Ake Lundkvist; Michèle Bouloy; Clas Ahlm; Göran Bucht
Journal:  Virol J       Date:  2009-01-17       Impact factor: 4.099

9.  A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep.

Authors:  Bonto Faburay; William C Wilson; Natasha N Gaudreault; A Sally Davis; Vinay Shivanna; Bhupinder Bawa; Sun Young Sunwoo; Wenjun Ma; Barbara S Drolet; Igor Morozov; D Scott McVey; Juergen A Richt
Journal:  Sci Rep       Date:  2016-06-14       Impact factor: 4.379

10.  Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle.

Authors:  William C Wilson; Bonto Faburay; Jessie D Trujillo; Izabela Ragan; Sun-Young Sunwoo; Igor Morozov; Vinay Shivanna; Aaron Balogh; Kinga Urbaniak; D Scott McVey; Dashzeveg Bold; Natasha N Gaudreault; Erin E Schirtzinger; Wenjun Ma; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.